Trishakti Indus (531279)

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Extraordinary recent growth: sales up 357% and profit up 1000%, with latest quarter sales of ₹8 Cr and net profit of ₹2 Cr.
• ROE of 54.24% shows efficient use of a thin equity base.
• Piotroski F-Score of 7/9 indicates decent short-term financial health.
• PEG ratio of 0.05 suggests the market is pricing in very little if the high growth persists.

Concerns

• Valuation is rich: P/E of 33.55 and P/B of 7.01, with zero dividend yield.
• Growth is from a tiny base, so the 357% and 1000% figures may be misleading and unsustainable.
• Current price of ₹55.12 is below the stated 52-week range of ₹114.90–₹191.00 — a red flag for data quality or liquidity.
• Promoter holding and debt/equity are N/A; insufficient disclosure for a confident value decision.

AI Analysis

Looking at Trishakti Indus, I am reminded that in the stock market, the most interesting story is often a trap. A 357% sales jump and 1,000% profit growth sound spectacular, but they start from a very small base: latest quarter sales of ₹8 crore and profit of ₹2 crore. The market cap is ₹90 crore, so it is a microcap. A P/E of 33.55 and P/B of 7.01 are not prices I would pay unless the business has a durable moat. I see no such moat in diversified commercial services. The 54.24% ROE is eye-catching, but with book value only ₹7.86, high ROE can simply reflect thin equity, not franchise strength. ROCE of 14.15% is far more sober and tells me the underlying capital return is moderate. The Piotroski F-Score of 7/9 is pleasant, but it is a snapshot, not a durable advantage. The PEG ratio of 0.05 is mathematically attractive only if the 1000% profit growth is sustainable; base-effect growth rarely is. I also worry about what is not disclosed: no promoter holding, no debt-equity ratio, and a startling inconsistency between the current price of ₹55.12 and a stated 52-week range of ₹114.90 to ₹191.00. A price below the reported low makes me suspicious of the data or the liquidity. No dividend, so the patient owner gets no cash while waiting. For me, value is the intersection of a good business, a fair price, and trustworthy numbers. Trishakti fails at least two of those tests. I will stay on the sidelines until I can understand the earnings quality and capital needs. Extraordinary growth at a small cost is nice, but I have lived long enough to know that the graveyard is full of companies that once grew 1000%.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer